IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis

被引:60
作者
Deng, Zhenzhen [1 ]
Wang, Shengfeng [1 ]
Wu, Cuifang [1 ]
Wang, Chunjiang [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Dept Pharm, Changsha, Hunan, Peoples R China
关键词
IL-17; inhibitors; inflammatory bowel disease; FAERS database; pharmacovigilance; drug safety; PSORIATIC-ARTHRITIS; ULCERATIVE-COLITIS; PLAQUE PSORIASIS; CROHNS-DISEASE; SECUKINUMAB; INTERLEUKIN-17; PATIENT; ONSET;
D O I
10.3389/fphar.2023.1124628
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Few real-world studies have shown clear association between interleukin (IL)-17 inhibitors and inflammatory bowel disease (IBD) onset. This study investigated the reporting prevalence and evaluated the clinical features and management of IL-17 inhibitor-related IBD events.Methods: We used the US FDA Adverse Event Reporting System database and retrieved data, from 2015 to 2022, on IL-17 inhibitors to identify gastrointestinal inflammatory events and conduct disproportionality analyses by estimating the reporting odds ratios (RORs) and corresponding 95% confidence intervals (CIs). Furthermore, case reports and case series, from 2015 to 30 November 2022, on IBD induced by IL-17 inhibitors were collected for retrospective analysis.Results: A total of 388 cases of primary suspected IL-17 inhibitor-associated gastrointestinal events were reported (268 IBD and 120 colitis), including 348 cases involving secukinumab (SEC), 36 cases involving ixekizumab (IXE), and 4 cases involving brodalumab (BRO). Statistically significant reporting rates of total IBD events were observed for SEC and IXE (ROR = 2.13, 95% CI [1.96-2.30] and ROR = 2.79, 95% CI [2.39-3.27], respectively), whereas BRO did not trigger a safety signal. Twenty-nine studies, which included 34 cases, showed evidence of IBD, following SEC (79.4%) and IXE (20.6%) treatment. The median age was 42 years; typical initial symptoms included diarrhea (90.9%), abdominal pain (57.6%), bloody diarrhea (51.5%), and fever (36.4%). The median time to onset of IBD symptoms was 2.9 months. Some cases were accompanied by elevated white blood cell (WBC) count (87.5%), erythrocyte sedimentation rate (ESR; 85.7%), C-reactive protein (CRP; 100%), and fecal calprotectin (FC; 100%). Cessation of IL-17 inhibitors plus treatment with corticosteroids and TNF antagonists, as either monotherapy or in combination, could lead to complete clinical remission. The median time to remission after IL-17 inhibitor discontinuation was 4 weeks.Conclusion: IL-17 inhibitor treatment is associated with exacerbation and new onset of IBD and colitis. Obtaining a detailed patient history before initiation of treatment and monitoring gastrointestinal symptoms and intestinal inflammatory biomarkers during IL-17 inhibitor treatment is important for safe use of these drugs.
引用
收藏
页数:9
相关论文
共 56 条
[1]   A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab [J].
Achufusi, Ted George ;
Harnee, Prateek S. ;
Rawlins, Sekou .
CASE REPORTS IN MEDICINE, 2019, 2019
[2]   New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature [J].
Ali, Ailia K. ;
Torosian, Arman ;
Porter, Caroline ;
Bloomfeld, Richard S. ;
Feldman, Steven R. .
DERMATOLOGIC THERAPY, 2021, 34 (06)
[3]   Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis [J].
Burisch, Johan ;
Eigner, Wolfgang ;
Schreiber, Stefan ;
Aletaha, Daniel ;
Weninger, Wolfgang ;
Trauner, Michael ;
Reinisch, Walter ;
Narula, Neeraj .
PLOS ONE, 2020, 15 (05)
[4]   Gastroenterological safety of IL-17 inhibitors: a systematic literature review [J].
Caron, Benedicte ;
Jouzeau, Jean-Yves ;
Miossec, Pierre ;
Petitpain, Nadine ;
Gillet, Pierre ;
Netter, Patrick ;
Peyrin-Biroulet, Laurent .
EXPERT OPINION ON DRUG SAFETY, 2022, 21 (02) :223-239
[5]   Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23 [J].
Darch, K. M. ;
Holland, T. L. ;
Spelman, L. J. .
CASE REPORTS IN MEDICINE, 2020, 2020
[6]   Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data [J].
Deodhar, A. ;
Mease, P. J. ;
McInnes, I. B. ;
Baraliakos, X. ;
Reich, K. ;
Blauvelt, A. ;
Leonardi, C. ;
Porter, B. ;
Gupta, A. Das ;
Widmer, A. ;
Pricop, L. ;
Fox, T. .
ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
[7]   A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis [J].
Ehrlich, Dean ;
Jamaluddin, Nimah ;
Pisegna, Joseph ;
Padua, David .
CASE REPORTS IN GASTROINTESTINAL MEDICINE, 2018, 2018
[8]   Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease [J].
Eppinga, Hester ;
Poortinga, Sietske ;
Thio, Hok Bing ;
Nijsten, Tamar E. C. ;
Nuij, Veerle J. A. A. ;
van der Woude, C. Janneke ;
Vodegel, Robert M. ;
Fuhler, Gwenny M. ;
Peppelenbosch, Maikel P. .
INFLAMMATORY BOWEL DISEASES, 2017, 23 (10) :1783-1789
[9]   Paradoxical gastrointestinal effects of interleukin-17 blockers [J].
Fauny, Marine ;
Moulin, David ;
D'Amico, Ferdinando ;
Netter, Patrick ;
Petitpain, Nadine ;
Arnone, Djesia ;
Jouzeau, Jean-Yves ;
Loeuille, Damien ;
Peyrin-Biroulet, Laurent .
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (09) :1132-1138
[10]   Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review [J].
Fauny, Marine ;
D'Amico, Ferdinando ;
Bonovas, Stefanos ;
Netter, Patrick ;
Danese, Silvio ;
Loeuille, Damien ;
Peyrin-Biroulet, Laurent .
JOURNAL OF CROHNS & COLITIS, 2020, 14 (05) :686-693